🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. KHK4827

    KYOWA KIRIN AUSTRALIA PTY LTD

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  3. KHK7580

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Secondary Hyperparathyroidism

    phase 3 small molecule completed

    1 trial

  4. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  5. KVD900 150 mg

    ISTA Pharma Limited

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  6. KVD900 150 mg

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  7. KVD900 600 mg

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 3 small molecule active

    2 trials

  8. KVD900, KVD900

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  9. KVD900, KVD900

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  10. Kalydeco 150 mg film-coated tablets, VX-770 Film-coated tablet, Kalydeco 75 mg film-coated tablets, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, VX-770 Film-coated tablet, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination tablet, Kaftrio 75 mg/50 mg/100 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  11. Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kalydeco 59.5 mg granules in sachet, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-121/VX-661/VX-561 granules, VX-445/VX-661/VX-770 fixed-dose combination tablet, VX-121/VX-661/VX-561 Film-coated tablet, VX-121/VX-661/VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  12. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

  13. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  14. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  15. KarXT

    Bristol-Myers Squibb

    Bipolar Disorder Type I With Mania

    phase 3 small molecule active

    1 trial

  16. KarXT

    Bristol-Myers Squibb

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  17. KarXT, KarXT, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Mania or Mania with Mixed Features in Bipolar-I Disorder

    phase 3 small molecule active

    1 trial

  18. Ketamine Hydrochloride

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule active

    1 trial

  19. Ketamine Hydrochloride

    Camp4 Therapeutics Corp

    Suicide

    phase 3 small molecule terminated

    1 trial

  20. Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  21. Keverprazan Hydrochloride tablets + high dose amoxicillin

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education

    phase 3 small molecule active

    1 trial

  22. Kuvan®

    BioMarin Pharmaceutical Australia Pty Ltd

    Autistic Disorder

    phase 3 small molecule completed

    1 trial

  23. Kyprolis 60 mg powder for solution for infusion, Kyprolis 30 mg powder for solution for infusion, DARZALEX 1800 mg solution for injection, ENDOXAN omhulde tablet, omhulde tabletten, 50 mg, Cesnicabtagene autoleucel, Kyprolis 10 mg powder for solution for infusion, Dexamethason Teva 4 mg, tabletten, Bortezomib Accord 3.5 mg powder for solution for injection, Empliciti 300 mg powder for concentrate for solution for infusion., Dexamethason Activase 2 mg tabletten, Pomalidomide Accord 4 mg hard capsules, Emplic

    Disc Medicine

    relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  24. L-alanyl-L-glutamine dipeptide

    Hospital Authority, Hong Kong

    Coronary Artery Bypass

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources